Watershed Inc
Curing the Bladder Comfortably
Set VIMEO_VIDEO_ID in page.tsx to embed the pitch video
Currently Raised in this round
USD 1,065,009
of $5,000,000.00
Login to InvestView Offering CircularPurchased securities are not currently tradeable. Expect to hold your investment until the company lists on a national exchange or is acquired.
Classification
Drug Delivery
Regulatory Pathway
New Drug Application
Raising Via
Equity
Valuation Cap
$24M
Closes
May 1, 2026
Offering at a Glance
First in Human complete with excellent comfort and safety
Extends and improves on the standard of care
Novel intravesical drug delivery platform with broad pipeline potential across multiple bladder indications
Significant milestone in 2026: Phase 1b in patients with NMIBC
Enormous addressable market in bladder cancer with option to expand to OAB and IC indications
Problem
Bladder conditions such as Overactive Bladder (OAB), Interstitial Cystitis (IC), and bladder cancer affect over 100 million people worldwide.
Existing treatments are either systemic (oral medications causing widespread side effects), invasive (surgery, injections under general anaesthesia), or poorly tolerated.
Patient compliance is low—up to 70% of patients discontinue oral OAB medications within the first year due to side effects like dry mouth, constipation, and cognitive impairment.
There is a critical unmet need for a targeted, minimally invasive drug delivery method that treats the bladder locally without the systemic burden.
Solution
Watershed has developed a proprietary intravesical drug delivery platform that instils therapeutic agents directly into the bladder via a standard catheter procedure.
The platform achieves sustained, targeted drug release at the site of disease—maximising efficacy while dramatically reducing systemic exposure and associated side effects.
The device is designed for in-clinic administration, does not require general anaesthesia, and is compatible with multiple drug payloads—creating a pipeline of indications from a single platform.
Phase 1 First-in-Human data demonstrated an excellent safety and tolerability profile, with no serious adverse events reported across all dose cohorts, validating the platform's clinical potential.
Product
Watershed's proprietary intravesical drug delivery device is a catheter-compatible system designed to instil therapeutic agents directly into the bladder lumen. The device achieves sustained, controlled-release drug exposure at the site of disease for up to 7 days following a single in-clinic procedure.
The platform is drug-agnostic and has been validated with multiple small-molecule agents, enabling a pipeline approach: the same delivery technology can be paired with different payloads to address distinct bladder conditions including Non-Muscle-Invasive Bladder Cancer (NMIBC), Overactive Bladder (OAB), and Interstitial Cystitis (IC).
Phase 1 First-in-Human data confirmed excellent safety and tolerability across all dose cohorts with no serious adverse events. Phase 1b enrollment is ongoing in patients with NMIBC, with topline data expected in 2026.
Market
Bladder conditions represent one of the most underserved areas in urology. Over 100 million patients worldwide are affected by bladder cancer, overactive bladder, or interstitial cystitis — yet current treatments are either poorly tolerated, minimally effective, or require invasive procedures under general anaesthesia.
$4.2B
Bladder Cancer (NMIBC)
Global market by 2028
$6.8B
Overactive Bladder
Global market by 2027
$2.1B
Interstitial Cystitis
Global market by 2030
$13B+
Total Addressable Market
Combined bladder indications
Team
Topher Kinsella, MD
CEO & Co-Founder
Board-certified urologist with 15+ years of clinical and surgical experience. Led the clinical design of the Phase 1 trial.
Sarah Chen, PhD
Chief Scientific Officer
PhD in drug delivery and biomaterials from MIT. Former Director of R&D at a leading urology biotech.
James O'Brien
Chief Financial Officer
Former investment banker with 12 years in healthcare capital markets. Structured over $500M in biotech transactions.
Financials
Risks
INVESTMENTS ON MEDTECH SYNDICATES ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK. ONLY INVEST IF YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT.
Clinical development risk: Watershed is a pre-revenue clinical-stage company. The product has completed Phase 1 but must successfully complete Phase 1b, Phase 2, and Phase 3 trials before FDA approval can be sought. Clinical trials may fail at any stage.
Regulatory risk: FDA approval is not guaranteed. The regulatory pathway for intravesical drug delivery devices is complex and subject to change.
Funding risk: The company will require additional capital beyond this offering to reach commercialisation. Future funding rounds may dilute existing investors.
Liquidity risk: Purchased securities are not currently tradeable. Investors should expect to hold their investment for an extended period—potentially 5–10 years—until a liquidity event such as an IPO or acquisition.
Important Message: INVESTMENTS ON MEDTECH SYNDICATES ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK. MedTech Syndicates is neither a registered broker-dealer, investment advisor, nor funding portal. All securities offerings are conducted through ICON Capital Group LLC, a FINRA/SIPC member firm. Regulation CF offerings are available to all investors; Regulation D offerings are available to accredited investors only. Please review all offering documents carefully before investing.